Agios leukemia drug shows promise in tiny, early study

April 6, 2014 2:36 PM

19 0

(Reuters) - An experimental drug being developed by Agios Pharmaceuticals Inc showed promising anti-cancer activity in a tiny Phase I study of patients with relapsed acute myeloid leukemia (AML), according to data presented on Sunday.

Of seven patients available to be evaluated following a 28-day cycle of treatment with the drug, AG-221, six had what researchers deemed objective responses to the medicine.

Read more

To category page